Home > Boards > US Listed > Biotechs > Stemline Therapeutics (STML)

Stemline Therapeutics target raised to $70 at Aegis

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biocqr Member Profile
Member Level 
Followed By 38
Posts 2,781
Boards Moderated 0
Alias Born 08/24/05
160x600 placeholder
Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Jap... GlobeNewswire Inc. - 10/8/2019 7:30:00 AM
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress GlobeNewswire Inc. - 10/1/2019 7:30:00 AM
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress GlobeNewswire Inc. - 9/27/2019 7:30:00 AM
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 4:01:00 PM
Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 9:32:15 AM
Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 9/5/2019 7:30:00 AM
Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/9/2019 4:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 1:18:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/9/2019 1:16:29 PM
Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock GlobeNewswire Inc. - 8/8/2019 10:23:47 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/8/2019 6:10:20 AM
Stemline Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire Inc. - 8/7/2019 4:25:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:37:16 PM
Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS® GlobeNewswire Inc. - 8/6/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/2/2019 7:31:04 AM
Stemline Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019 GlobeNewswire Inc. - 7/29/2019 7:00:00 AM
Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its An... GlobeNewswire Inc. - 7/8/2019 5:50:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:18:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:09 PM
biocqr Member Level  Wednesday, 10/30/13 01:36:39 PM
Re: None
Post # of 67 
Stemline Therapeutics target raised to $70 at Aegis Capital (29.14 -1.12)

Aegis Capital raises their STML tgt to $70 from $40. Co has reported favorable preclinical data for its lead drug candidate, SL-401, in areas such as multiple myeloma and chronic myelogenous leukemia (CML). In firm's view, market authorization for SL-401 in MM and additional niche hematological malignancies on top of blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia could drive peak sales potential from $800mm to over $3bn. Further, Stemline's follow-up candidate to SL-401, known as SL-501, is a variant interleukin-3-diphtheria toxin fusion protein that could be used to target CML as a new product.


Read more: http://www.briefing.com/InPlayEq/InPlay/InPlayDual.htm#ixzz2jEBkpn66

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist